Proteasome Inhibitor News and Research

RSS

Combination treatment strategy uses cells' waste removal functions to dismantle multiple myeloma

New research out of VCU Massey Comprehensive Cancer Center provides promising evidence for an innovative combination treatment strategy that uses cells' waste removal functions to effectively dismantle multiple myeloma.

13 Jul 2026

Natural compound obakulactone shows therapeutic potential for rheumatoid arthritis

A new study published in Engineering reveals that obakulactone (OL), a natural tetracyclic triterpenoid isolated from Phellodendri cortex, exerts a therapeutic effect on rheumatoid arthritis (RA) by promoting the degradation of acyl coenzyme A thioesterase 1 (ACOT1) via the ubiquitin‒proteasome pathway and restoring the homeostasis of unsaturated fatty acids.

25 Apr 2026

Study identifies PPP2R5C blood marker that may detect Alzheimer’s disease earlier

Emerging evidence suggests reduced plasma PPP2R5C levels may serve as an early indicator of Alzheimer’s disease before overt clinical symptoms appear. The protein appears linked to tau regulation, autophagy pathways, and cognitive decline, supporting its potential diagnostic relevance.

22 Feb 2026

Chronic inflammation shapes cancer progression and immunotherapy response

Chronic inflammation is both a driver and suppressor of cancer depending on context. Key players-NF-κB, IL-6, STAT3, TAMs, MDSCs, and Tregs-orchestrate a tumor-permissive microenvironment.

16 Feb 2026

Clonogenic hepatocytes identified as engines of liver development

In a new study published in the Journal of Hepatology, researchers from the San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) show that only 15–20% of hepatocytes in newborn mice - dubbed clonogenic hepatocytes - are responsible for generating over 90% of the adult liver mass.

29 Aug 2025

Blocking an inflammatory receptor in the retinas of aging mice improves retinal health

A new research paper was published in Aging (Aging-US) on January 31, 2025, in Volume 17, Issue 2, titled "Cysteinyl leukotriene receptor 1 modulates retinal immune cells, vascularity and proteolytic activity in aged mice."

25 Mar 2025

New trial explores BAFF CAR T-cell therapy for relapsed myeloma

University Hospitals (UH) Seidman Cancer Center hematologist-oncologist Leland Metheny, MD, is leading the trial.

14 Aug 2024

Evolving treatment paradigms in multiple myeloma could improve patient outcomes

The treatment landscape for multiple myeloma, the second most common blood cancer, is shifting rapidly, with newly diagnosed patients increasingly being treated with a four-part drug combination that includes a new immunotherapy agent.

24 May 2024

Proteasomes: Expanding roles beyond cellular waste management

The typical job of the proteasome, the garbage disposal of the cell, is to grind down proteins into smaller bits and recycle some of those bits and parts.

13 Apr 2024

New structural insights pave the way for drug-resistant malaria therapies

Structural insights into a potent antimalarial drug candidate's interaction with the malaria parasite Plasmodium falciparum have paved the way for drug-resistant malaria therapies, according to a new study by researchers at Weill Cornell Medicine and Van Andel Institute.

18 Jan 2024

New PCNA inhibitor AOH1996 shows selective cancer cell killings and tumor suppression potential

Study described a small molecule inhibitor of proliferating cell nuclear antigen (PCNA) that selectively kills cancer cells.

4 Aug 2023

Interactions between SIRT5 and SARS-CoV-2 Nsp14 protein

In a new study, researchers investigated the interactions between sirtuin 5 (SIRT5) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nonstructural protein (Nsp14) protein.

14 Sep 2022

SARS-CoV-2 spike protein downregulates ACE2 expression

In a new study, researchers observed the downregulation of ACE2 by SARS-CoV-2.

11 Jul 2022

Study shows the SARS-CoV-2 accessory protein ORF7a inhibits HLA-I surface expression levels in human cells

Researchers identified a single viral gene product, the accessory factor ORF7a, facilitating SARS-CoV-2 immune evasion by downregulating the surface expression of MHC class I molecules.

1 Jun 2022

Research opens up new avenues for cancer treatment

Researchers at Koç University discovered why a promising class of cancer treatments fail, and their findings point to how such treatments might be made to work.

28 Jan 2022

$Clinical trial shows preliminary efficacy of all-oral regimen for patients with lenalidomide-refractory multiple myeloma$

Clinical trial shows preliminary efficacy of all-oral regimen for patients with lenalidomide-refractory multiple myeloma

Early results from an Alliance for Clinical Trials in Oncology randomized clinical trial of adults with multiple myeloma relapsing on frontline lenalidomide therapy showed that adding ixazomib (Ninlaro®) to pomalidomide and dexamethasone as part of second line therapy extended the length of time patients lived before their disease worsened (progression-free survival) compared with patients who received pomalidomide and dexamethasone.

21 Dec 2021

Combination therapy shows potential for treating lung cancer

Most lung cancers are of a type called non-small-cell lung carcinoma (NSCLC). This type of cancer is relatively insensitive to chemotherapy, so NSCLC therapies are usually based on drug treatment.

22 Jan 2021

Clinical investigators present abstracts on hematological malignancies at ASH Annual Meeting and Exposition

Clinical investigators from Hackensack Meridian Health John Theurer Cancer Center (JTCC), a member of the Georgetown Lombardi Comprehensive Cancer Center consortium, are to present updates on treatment advances in multiple myeloma (MM), mantle cell lymphoma (MCL), and other types of B-cell lymphoma (BCL) as well as leukemia at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, to be held virtually from December 5-8, 2020.

7 Dec 2020

Exploring the effects of smoking tobacco on COVID-19 risk

A study conducted by researchers in China has shed light on how certain tobacco compounds might prevent cells from becoming infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that causes coronavirus disease 2019 (COVID-19).

14 Oct 2020

Blocking the self-destruction process of enzymes can mitigate age-related diseases

Stopping the cannibalistic behavior of a well-studied enzyme could be the key to new drugs to fight age-related diseases, according to a new study published online in Nature Cell Biology.

30 Sep 2020